The moderate to severe types of ulcerative colitis (UC), a chronic inflammatory bowel disease, provide a substantial burden to patients and healthcare professionals alike. The therapy landscape has changed drastically due to recent developments in small-molecule and biological medicines, which have opened up new possibilities for illness management. The American Gastroenterological Association's (AGA) Evidence Synthesis for 2024 is examined in this publication. It examines the most recent innovative treatments for moderate to severe UC. In this research, we look at the new developments in UC treatment by analysing the safety records, long-term effects, and effectiveness of several medications, such as IL inhibitors, JAK inhibitors, integrin receptor antagonists, and TNF inhibitors.
Not applicable.
The authors state that they have no conflicts of interest regarding this article.
The author confirms that they were solely responsible for the study's planning, data acquisition, results interpretation, and manuscript writing.q
The authors received no financial support for the research, authorship, or publication of this article from any funding agencies.
Not applicable.
My thanks go to those who assisted with this study and manuscript preparation, and to the peer reviewers for their constructive feedback.
-